Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7

Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score... IntroductionGleason score (GS) at diagnostic biopsy is an important parameter for therapeutic decision‐making in men with prostate cancer. According to the International Society of Urologic Pathology (ISUP) and World Health Organisation (WHO) guidelines, pathologists should grade each biopsy containing cancer separately, provided that individual cores can be identified, and may also give an overall score for the entire case. However, prostate cancer heterogeneity and multifocality might result in variability of individual biopsy core GS. In such cases it is not evident which GS should be recorded for patient stratification and treatment. For instance, a patient might have one biopsy core presenting with 6 mm GS 3 + 3 = 6 and another biopsy core with 2 mm GS 4 + 3 = 7. In this case, stratification might be based either on the overall GS 3 + 4 = 7 or highest GS 4 + 3 = 7. Discordancy between overall and highest GS particularly affects men with GS 7, as optimal individual therapeutic strategies are not well defined in this subgroup. Studies on overall and highest GS show conflicting results, and have not focused on GS 3 + 4 = 7 in particular. We aimed to compare the clinicopathological characteristics and outcome of men with overall biopsy GS 3 + 4 = 7 with highest GS 3 + 4 = 7 (HI = OV) to those with highest GS > 3 + 4 = 7 (HI > OV).MethodsPatient http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Histopathology Wiley

Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7

Loading next page...
 
/lp/wiley/characteristics-and-outcome-of-prostate-cancer-patients-with-overall-4znGbOJWhO
Publisher
Wiley
Copyright
Copyright © 2018 John Wiley & Sons Ltd
ISSN
0309-0167
eISSN
1365-2559
D.O.I.
10.1111/his.13427
Publisher site
See Article on Publisher Site

Abstract

IntroductionGleason score (GS) at diagnostic biopsy is an important parameter for therapeutic decision‐making in men with prostate cancer. According to the International Society of Urologic Pathology (ISUP) and World Health Organisation (WHO) guidelines, pathologists should grade each biopsy containing cancer separately, provided that individual cores can be identified, and may also give an overall score for the entire case. However, prostate cancer heterogeneity and multifocality might result in variability of individual biopsy core GS. In such cases it is not evident which GS should be recorded for patient stratification and treatment. For instance, a patient might have one biopsy core presenting with 6 mm GS 3 + 3 = 6 and another biopsy core with 2 mm GS 4 + 3 = 7. In this case, stratification might be based either on the overall GS 3 + 4 = 7 or highest GS 4 + 3 = 7. Discordancy between overall and highest GS particularly affects men with GS 7, as optimal individual therapeutic strategies are not well defined in this subgroup. Studies on overall and highest GS show conflicting results, and have not focused on GS 3 + 4 = 7 in particular. We aimed to compare the clinicopathological characteristics and outcome of men with overall biopsy GS 3 + 4 = 7 with highest GS 3 + 4 = 7 (HI = OV) to those with highest GS > 3 + 4 = 7 (HI > OV).MethodsPatient

Journal

HistopathologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off